ANTX - AN2 Therapeutics Inc

ANTX - AN2 Therapeutics Inc

https://www.an2therapeutics.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

AN2 Therapeutics Plunges 66% in a Month: Here's Why - Arcturus Therapeutics ( NASDAQ:ARCT ) , AN2 Therapeutics ( NASDAQ:ANTX )

Benzinga • 1 year ago • score: -0.01

AN2 Therapeutics ANTX, a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.

AN2 Therapeutics ( ANTX ) Plunges 66% in a Month: Here's Why

Zacks Commentary • 1 year ago • score: 0.01

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

Citizens And 2 Other Penny Stocks Insiders Are Buying - Citizens ( NYSE:CIA )

Benzinga • 1 year, 1 month ago • score: -0.05

The Dow Jones index closed higher by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading ...

Why Is AN2 Therapeutics Stock Trading Lower On Friday? - AN2 Therapeutics ( NASDAQ:ANTX )

Benzinga • 1 year, 1 month ago • score: 0.10

On Thursday, AN2 Therapeutics, Inc. ANTX released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen ( OBR ) in treatment-refractory mycobacterium avium complex ( MAC ) lung disease.

Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics ( ANTX ) Looks Ripe for a Turnaround

Zacks Commentary • 1 year, 3 months ago • score: 0.22

AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Anthem, Inc., is a health benefits company in the United States. The company is headquartered in Indianapolis, Indiana.

52W High

$1.68

52W Low

$0.98

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.08

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.11

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.50

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

25.39%

Institutions (25–75% balanced)

39.54%

Shares Outstanding

27,326,200

Float

17,736,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.25

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.45%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0512

Previous

0.0466

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025